Article
Four Ways to Turn Disqualification Data into Action
blog.careboxhealth.com
Quoted on this wiki
Every place a page here uses this source, in the order the words come in it.
“But the view is only valuable if it drives action.” Data from a global pharmaceutical sponsor's Phase 1 study for advanced solid tumors, which covered seven tumor types including colorectal, endometrial, gallbladder, kidney, lung, ovarian, and thyroid cancers, illustrates the point. The network recorded more than 6,400 completed questionnaires in the reporting period, with an overall match rate of approximately 50%. A 50% match rate means more than 3,000 patients who actively sought a clinical trial option did not qualify, and each of those disqualifications was categorized by the specific eligibility criterion that caused the failure. The match rate varied dramatically by condition, ranging from 9.8% for ovarian cancer to 67.6% for colorectal cancer. That variation is telling a specific story about each condition's patient population relative to the protocol's eligibility requirements, and it looks very different depending on which condition you examine. For lung cancer, the network saw 1,232 completed questionnaires with 620 patients matching (50.3%), leaving 612 patients who actively sought a lung cancer trial and did not qualify. The disqualification profile was spread across several criteria: primary diagnosis accounted for 44.7% of non-matches, metastatic status for 30.9%, and ECOG performance score for 15%. That distribution points to a population readiness challenge — patients seeking the trial represent a broad range of disease stages and functional statuses, and the protocol's eligibility window captures only a portion of that population. Ovarian cancer tells a completely different story. With 3,545 completed questionnaires and only 346 matches, the 9.8% match rate was the lowest across all seven tumor types. The driver was concentrated rather than distributed: 62% of unmatched ovarian cancer patients failed on primary diagnosis specificity, meaning the vast majority of ovarian cancer patients completing the questionnaire did not have the specific ovarian subtype the trial required.